A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis

Abstract: Despite a recent increase in therapeutic options, patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) eventually require novel therapies. We conducted a phase 1 trial of blinatumomab and lenalidomide in R/R B-NHL. Three dose levels representing 2 schedules were explor...

Descripción completa

Detalles Bibliográficos

Autores principales:	Joseph M. Tuscano, Tamer Othman, Paul Frankel, Christopher Ruel, Christina Poh, Samantha Herbert, Emanual Maverakis, Alexander A. Merleev, Guillaume Luxardi, Mehrdad Abedi, Raghuveer Ranganathan, Dipenkumar Modi, Jasmine Zain, Elizabeth L. Budde, Matthew Mei, Aaron S. Rosenberg, Rasmus T. Hoeg, Caitlin Costello, Francine M. Foss, Basem M. William, H. Kent Holland, Elad Sharon, Howard Streicher, Alexy Danilov, Edward Newman
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2026-02-01
Colección:	Blood Advances
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S2473952925007049
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!